FRLN
Income statement / Annual
Last year (2022), Freeline Therapeutics Holdings plc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Freeline Therapeutics Holdings plc's net income was -$88.97 M.
See Freeline Therapeutics Holdings plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.74 M |
$2.39 M |
$1.93 M |
$1.55 M |
$0.00 |
| Gross Profit |
-$1.74 M |
-$2.39 M |
-$1.93 M |
-$1.55 M |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$66.20 M
|
$95.43 M
|
$76.15 M
|
$47.04 M
|
$34.19 M
|
| General & Administrative
Expenses |
$30.66 M
|
$44.57 M
|
$26.30 M
|
$16.60 M
|
$6.79 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$30.66 M
|
$44.57 M
|
$26.30 M
|
$16.60 M
|
$6.79 M
|
| Other Expenses |
-$1.57 M |
-$2.09 M |
-$15.27 M |
-$10.60 M |
-$390,000.00 |
| Operating Expenses |
$95.29 M |
$137.91 M |
$87.18 M |
$53.05 M |
$32.72 M |
| Cost And Expenses |
$95.29 M |
$137.91 M |
$87.18 M |
$53.05 M |
$32.72 M |
| Interest Income |
$904,000.00 |
$403,951.00 |
$275,000.00 |
$74,306.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$151,000.00 |
| Depreciation &
Amortization |
$1.27 M
|
$9.24 M
|
$17.18 M
|
$12.14 M
|
$970,000.00
|
| EBITDA |
-$97.17 M
|
-$133.14 M
|
-$85.27 M
|
-$51.51 M
|
-$32.14 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$9.84 M
|
$2.33 M
|
$6.26 M
|
$9.88 M
|
-$470,797.00
|
| Income Before Tax |
-$88.60 M |
-$140.05 M |
-$96.19 M |
-$53.77 M |
-$33.26 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$368,000.00 |
$342,000.00 |
$129,000.00 |
$141,000.00 |
$27,000.00 |
| Net Income |
-$88.97 M |
-$140.39 M |
-$96.32 M |
-$53.91 M |
-$33.28 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-22.52 |
-58.98 |
-102.09 |
-127.39 |
-78.65 |
| EPS Diluted |
-22.52 |
-58.98 |
-102.09 |
-127.39 |
-78.65 |
| Weighted Average Shares
Out |
$3.95 M
|
$2.38 M
|
$943,522.00
|
$423,188.00
|
$423,188.00
|
| Weighted Average Shares
Out Diluted |
$3.95 M
|
$2.38 M
|
$943,523.00
|
$423,188.00
|
$423,188.00
|
| Link |
|
|
|
|
|
